Mayrer A R, Miniter P, Andriole V T
Am J Med. 1983 Jul 28;75(1B):59-70. doi: 10.1016/0002-9343(83)90074-8.
Immunopathologic responses to urinary Tamm-Horsfall protein in the development of chronic pyelonephritis were examined by four different approaches. First, in a rabbit model, tubulointerstitial nephritis developed in 64 of 102 rabbits injected intravenously with urine or rabbit Tamm-Horsfall protein as compared with only one of 17 rabbits in two control groups. Circulating cytotoxic lymphocytes plus immunoglobulin G (IgG) antibodies against Tamm-Horsfall protein were found in 51 percent of challenged (urine or Tamm-Horsfall protein) rabbits with tubulointerstitial nephritis as compared with only 8 percent of those without it (p less than 0.001). Second, in a porcine model of reflux nephropathy, 16 of 21 pigs with pyelographic findings indicative of reflux had elevated serum titers of anti-Tamm-Horsfall protein antibody as compared with 0 of 13 with normal pyelograms. Five of 10 refluxing pigs tested also had circulating lymphocytes that were cytotoxic in the presence of Tamm-Horsfall protein as compared with 0 of 13 with normal pyelograms. Third, in human studies, 12 of 49 patients with recurrent nephrolithiasis demonstrated abnormal elevations in anti-Tamm-Horsfall protein antibody; 13 of 49 had an abnormality in one of two assays of cell-mediated immunity to Tamm-Horsfall protein as compared with 0 of the normal control subjects. These abnormalities were not associated with overt obstruction or bacteriuria, but appeared to be more common in patients with recent onset and active recurrent nephrolithiasis. Lastly, an inhibitor of the binding reaction between human Tamm-Horsfall protein and its IgG antibody was detected in extracts of three uropathic coliforms. The inhibitors were partially purified by chromatographic means. Preliminary immunoautoradiographic studies revealed three or less protein-containing subunits of Escherichia coli that cross-reacted with anti-Tamm-Horsfall protein antibody. These studies suggest that autoimmune responses to Tamm-Horsfall protein may occur after exposure to Tamm-Horsfall protein by intravenous challenge, urinary reflux, or recurrent nephrolithiasis. This autoimmune response to Tamm-Horsfall protein may be the pathogenetic mechanism by which these factors, including bacteriuria, contribute to chronic pyelonephritis.
通过四种不同方法研究了慢性肾盂肾炎发病过程中对尿中Tamm-Horsfall蛋白的免疫病理反应。首先,在兔模型中,102只静脉注射尿液或兔Tamm-Horsfall蛋白的兔子中有64只发生了肾小管间质性肾炎,而两个对照组的17只兔子中只有1只发病。在发生肾小管间质性肾炎的受攻击(注射尿液或Tamm-Horsfall蛋白)兔子中,51%发现有循环细胞毒性淋巴细胞加抗Tamm-Horsfall蛋白的免疫球蛋白G(IgG)抗体,而未发生该病的兔子中这一比例仅为8%(P<0.001)。其次,在反流性肾病的猪模型中,21只肾盂造影有反流表现的猪中有16只抗Tamm-Horsfall蛋白抗体血清滴度升高,而13只肾盂造影正常的猪中无一例升高。10只进行检测的反流猪中有5只在有Tamm-Horsfall蛋白存在时也有循环细胞毒性淋巴细胞,而13只肾盂造影正常的猪中无一例有此情况。第三,在人体研究中,49例复发性肾结石患者中有12例抗Tamm-Horsfall蛋白抗体异常升高;49例中有13例在针对Tamm-Horsfall蛋白的细胞介导免疫的两项检测中有一项异常,而正常对照组无一例异常。这些异常与明显梗阻或菌尿无关,但似乎在近期发病且复发性肾结石活动期的患者中更常见。最后,在三种尿路致病性大肠埃希菌的提取物中检测到一种人Tamm-Horsfall蛋白与其IgG抗体结合反应的抑制剂。通过色谱方法对这些抑制剂进行了部分纯化。初步免疫放射自显影研究显示,有三种或更少含蛋白亚基的大肠杆菌与抗Tamm-Horsfall蛋白抗体发生交叉反应。这些研究提示,静脉注射攻击暴露于Tamm-Horsfall蛋白、尿液反流或复发性肾结石后,可能会发生针对Tamm-Horsfall蛋白的自身免疫反应。这种针对Tamm-Horsfall蛋白的自身免疫反应可能是包括菌尿在内的这些因素导致慢性肾盂肾炎的发病机制。